Loading people...
Julie Grant is a General Partner at Canaan Partners, a prominent early-stage venture capital firm. She is a leading investor in the healthcare sector, focusing on innovative digital health, biotechnology, and medical device companies.
Julie Grant primarily invests in healthcare companies, with a specific emphasis on digital health solutions, biotechnology firms developing novel therapeutics, and medical device innovations. She seeks companies that leverage technology to improve patient outcomes and healthcare efficiency.
Julie Grant works as a General Partner at Canaan Partners, a well-known venture capital firm that invests in early-stage technology and healthcare companies.
Julie Grant stands as a distinguished General Partner at Canaan Partners, a leading venture capital firm renowned for its early-stage investments in technology and healthcare. At Canaan, Julie plays a pivotal role in shaping the future of healthcare by identifying and backing visionary entrepreneurs and innovative companies. Her investment thesis is deeply rooted in the belief that technology can profoundly transform healthcare, making it more efficient, accessible, and effective for patients worldwide.
Grant's investment focus areas are primarily within the healthcare sector, encompassing a broad spectrum of sub-domains. She is particularly keen on digital health solutions that leverage software, data analytics, and connectivity to improve patient outcomes, streamline clinical workflows, and enhance the overall healthcare experience. Beyond digital health, her portfolio extends to cutting-edge biotechnology firms developing novel therapeutics and diagnostics, as well as medical device companies creating next-generation tools and technologies for diagnosis and treatment. She seeks out companies that demonstrate strong scientific foundations, clear market needs, and scalable business models.
Before joining Canaan Partners, Julie Grant built a robust career foundation in healthcare investment and corporate development. She previously served as a healthcare investor at Baxter Ventures, the corporate venture arm of Baxter International, where she gained invaluable experience in strategic investments within the medical products industry. Prior to her tenure at Baxter Ventures, she honed her expertise in corporate development at Baxter International and in healthcare investment banking at Credit Suisse. This diverse background has equipped her with a comprehensive understanding of both the financial and operational aspects of healthcare innovation, from early-stage development to market commercialization. Julie holds an MBA from Harvard Business School and a BA from Dartmouth College.
Throughout her career, Julie Grant has been instrumental in supporting numerous companies that have gone on to achieve significant milestones. While specific public disclosures of all her notable investments can vary, her work at Canaan and previous roles has seen her involved with companies that are making substantial impacts in areas like mental health, chronic disease management, and precision medicine. Her commitment to fostering innovation and her deep industry knowledge make her a respected figure in the venture capital community, particularly within the dynamic and critical field of healthcare investing.
Julie Grant is a General Partner at Canaan Partners in the San Francisco Bay Area, where she co-leads the life sciences investment practice focusing on early-stage biopharma companies. Before joining Canaan in 2013, she worked at Genentech in corporate development and commercial strategy for oncology products, having previously earned degrees from Yale University, the University of Cambridge, and a master of business administration from Stanford University. Her portfolio features numerous successful company incubations and therapeutics investments, notably leading to the 2021 initial public offerings of Day One Biopharmaceuticals and Tyra Biosciences. In April 2023, she helped close $850 million across two new Canaan funds and was appointed to the National Cancer Advisory Board by President Biden. Grant continues to focus on founding and financing early-stage biotechnology startups that develop novel therapeutics to advance patient care.
